Scleroderma Therapeutics Market || Driving Factors and Market Challenges Analysis till 2030

The report "Global Scleroderma Therapeutics Market, By Drug Class (Immunosuppressors, Phosphodiesterase 5 Inhibitors – PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Analgesics, and Others), By Indication (Systemic and Localized), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029”.

Key Highlights:

In March 2020, Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved ZEPOSIA (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
In September 2019, Processa Pharmaceuticals announced that it has entered into a global licensing agreement with Akashi Therapeutics to possibly develop and market HT-100, Akashi’s candidate to treat diseases associated with tissue fibrosis (scarring) and inflammation, including scleroderma.
In July 2019, Kadmon Holdings Company started a Phase 2 clinical trial testing its inhibitor KD025, with the first patient with diffuse cutaneous systemic sclerosis (SSc) being dosed.

Download Free sample copy of this report @
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4415

Analyst View:

The growing incidence and screening rates of Scleroderma is the major factor driving growth of the global scleroderma therapeutics market. According to the international reports from Japan and Britain, the incidence of systemic scleroderma is about 35 instances per 1 million adults. Scleroderma is a longstanding disease and needs regular dose of drugs. Additionally, increase in disposable income and growth in the awareness of preventive healthcare among the population is expected to increase the scleroderma therapeutics market.

Nevertheless, ongoing R&D in the field of Scleroderma diagnosis and therapeutics is expected to create lucrative opportunities throughout the forecast period.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Scleroderma Therapeutics Market”, By Drug Class (Immunosuppressors, Phosphodiesterase 5 Inhibitors – PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Analgesics, and Others), By Indication (Systemic and Localized), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029

Key Market Insights from the report:

The global scleroderma therapeutics market accounted for US$ 1.7 billion in 2019 and is estimated to be US$ 3.2 billion by 2029 and is anticipated to register a CAGR of 6.6%. The market report has been segmented on the basis of drug class, indication, and region.

By drug class, immunosuppressants segment accounts for the highest share as this class contains several biologics from established players such as Roche. Biologics and small molecule immunosuppressants are a surging segment with numerous pipeline drugs for scleroderma focusing on this class.
By indication, localized scleroderma segment presently accounts for a small share in this market but is projected to surge during the forecast period with the predicted launch of a first-in-class therapy, FCX-013 by Fibrocell.
By region, North America dominated the target market in 2019, owing to access to newly developed immunosuppressants along with favourable reimbursement scenario. Europe accounts for the lower share as compared to the U.S. majorly due to developed use of generics and biosimilars for off-label treatment of scleroderma.

Competitive Landscape:

The prominent player operating in the global scleroderma therapeutics market includes F. Hoffman La-Roche Ltd., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Akashi Therapeutics, Celgene Corp., Bayer AG, Seattle Genetics, Inc., Prometic Life Sciences, Inc., Emerald Health Pharmaceuticals, Kadmon Holdings, Inc., and Cytori Therapeutics, Inc.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Request discount:-
https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/4415

Explains an overview of the product portfolio, including product development, planning, and positioning
Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
Detailed analysis of the market revenue over the forecasted period.
Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
Study on the segments that are anticipated to dominate the market.
Study on the regional analysis that is expected to register the highest growth over the forecast period

Contact Us:
Mr Alex (Sales Manager)
Prophecy Market Insights
Phone: +1 860 531 2701
Email: sales@prophecymarketinsights.com“

About us:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.

This release was published on openPR.